NCT05389930 is a Phase 2 clinical trial of THC-dominant cannabis in Alcohol Drinking, sponsored by Brown University.

Who is sponsoring NCT05389930?

NCT05389930 is sponsored by Brown University.

What drugs are being tested in NCT05389930?

Interventions in NCT05389930: THC-dominant cannabis, CBD-dominant cannabis, Cannabis placebo, Alcohol, Alcohol placebo.

What condition does NCT05389930 study?

NCT05389930 studies Alcohol Drinking, Cannabis Use, Cannabis, Alcohol Use Disorder.

Is NCT05389930 still recruiting?

NCT05389930 is currently recruiting now. Last updated 6 August 2024.

Last reviewed 2024-08-06 · How we verify

NCT05389930

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cannabis' Impact on Alcohol Consumption

Recruiting now Phase 2 Last updated 6 August 2024

What this trial tests

Phase 2 trial testing THC-dominant cannabis in Alcohol Drinking in 350 participants. Currently enrolling.

Timeline

16 March 2023

Primary endpoint
31 March 2027

31 March 2027

Quick facts

Lead sponsor	Brown University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	double
Primary purpose	basic science
Enrollment	350
Start date	16 March 2023
Primary completion	31 March 2027
Estimated completion	31 March 2027
Sites	1 location across United States

Drugs / interventions tested

THC-dominant cannabis — full drug profile →
CBD-dominant cannabis — full drug profile →
Cannabis placebo
Alcohol — full drug profile →
Alcohol placebo — full drug profile →

Conditions studied

Alcohol Drinking — all drugs for Alcohol Drinking →
Cannabis Use — all drugs for Cannabis Use →
Cannabis — all drugs for Cannabis →
Alcohol Use Disorder — all drugs for Alcohol Use Disorder →

Sponsor

Brown University

Who can join

Adults 21 to 50, any sex, with Alcohol Drinking or Cannabis Use. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study employs a repeated measures experimental design to examine the effect of THC-dominant dose of cannabis and CBD-dominant dose of cannabis, relative to placebo, on subsequent drinking in an alcohol choice task in which participants choose either to drink or receive monetary reinforcement for drinks not consumed. Cannabis will be administered simultaneously with an alcohol-priming dose or alcohol placebo. The study will enroll up to 350 nontreatment-seeking heavy episodic alcohol drinkers who use cannabis weekly.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging medications and pharmacological treatment approaches for substance use disorders.
Raymond JS, Athanasopoulos AG, Badolato CJ, Doolan TJ, et al · · 2025 · cited 2× · PMID 39719161 · DOI 10.1016/j.pbb.2024.173952
Cannabidiol mitigates alcohol dependence and withdrawal with neuroprotective effects in the basolateral amygdala and striatum.
Dirik S, Doyle MR, Wood CP, Campo P, et al · · 2026 · cited 1× · PMID 40640509 · DOI 10.1038/s41386-025-02164-6

Verify or expand the search:

Other recruiting trials for Alcohol Drinking

Currently open trials in the same condition.

NCT07415707 — The GLUCID Study: Effect of Alcohol Reduction and Probiotic Interventions on Cognition and Brain Glucose Metabolism in N · NA · recruiting
NCT06815237 — Effects of Ketone Supplement and Alcohol on Brain Metabolism · Phase 2, PHASE3 · recruiting
NCT06994962 — Multi-Component Breath Alcohol Intervention Phase 3 · NA · recruiting
NCT05363878 — Development of a Culturally Grounded, Trauma-Informed Alcohol Intervention With a Reserve-Dwelling First Nation Group · NA · recruiting
NCT06309134 — The Healthy Families Bright Futures Program · NA · recruiting

Other Brown University trials

Trials by the same sponsor.

NCT07502872 — TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-g · Phase 2 · not yet recruiting
NCT07118618 — Probenecid Administration for Alcohol Craving and Consumption · Phase 2 · recruiting
NCT07398443 — Using Novel Behavioral Economic Measures to Characterize Dual Marijuana and Tobacco Use in Young Adults · NA · recruiting
NCT05901766 — Effect of Iodine-containing Multiple Micronutrient During Lactation on Infant Neurodevelopment · Phase 4 · not yet recruiting
NCT06974604 — Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05389930 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brown University
Last refreshed: 6 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05389930.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing